[1]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76-78.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(02):76-78.[doi:10.13798/j.issn.1009-153X.2020.02.005]
点击复制

TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2020年02期
页码:
76-78
栏目:
论著
出版日期:
2020-02-25

文章信息/Info

Title:
Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas
文章编号:
1009-153X（2020）02-0076-03
作者:
殷安安　陆　南　贺亚龙　章　翔　刘玉河
271000 山东泰安，中国人民解放军联勤保障部队第九六〇医院泰安院区神经外科（殷安安、陆　南、刘玉河）；710032 西安，空军军医大学西京医院神经外科（殷安安、贺亚龙、章　翔）
Author(s):
YIN An-an1; 2;  LU Nan1;  HE Ya-long2;  ZHANG Xiang2;  LIU Yu-he1.
1. Department of Neurosurgery, the 960th Hospital of PLA, Taian 271000, China; 2. Department of Neurosurgery, Xijing Hospital, Air Force Military Medical University, Xi’an 710032, China
关键词:
胶质母细胞瘤; TRIM38基因; 非CpG岛; DNA甲基化
Keywords:
TRIM38;  non-CpG island;  Methylation;  Glioblastomas
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2020.02.005
文献标志码:
A
摘要:
目的 探讨免疫基因TRIM38非CpG岛DNA甲基化在胶质母细胞瘤（GBM）中改变模式和临床意义。方法 利用公共数据库，比较TRIM38甲基化在GBM与非肿瘤脑组织（NTB）中的差异程度，并通过统计分析探讨该基因甲基化水平与基因表达、病人预后、生物学背景的关系。结果 纳入3组GBM（共509例）和3组NTB（共37例）样本。TRIM38基因非CpG岛DNA甲基化位点在GBM中呈低甲基化改变（P<0.05），而其基因表达呈现高表达改变（P<0.05），并且甲基化与基因表达呈显著负相关（P<0.05）。TRIM38低甲基化病人生存时间明显短于高甲基化组（P<0.05），甲基化水平是独立的预后影响因子（P<0.05）。TRIM38低甲基化GBM样本可能富集免疫调节及Toll样受体通路相关的基因簇。结论 TRIM38可能在GBM中通过非CpG岛低甲基化介导的基因异常表达上调，参与肿瘤发生、发展；TRIM38非CpG岛甲基化可能作为指导GBM预后评价的潜在生物标记物；TRIM38甲基化导致的预后差异很可能与Toll样受体通路及免疫调节的差异有关。
Abstract:
Objective To study the relationship of TRIM38 non-CpG island (CGI) DNA methylation with the prognosis in the patients with glioblastomas (GBMs). Methods By using experimental and clinical data acquired from the public databases, the degrees of DNA methylation of non-CGI open sea regions of TRIM38 in the GBMs tissues and non-tumor brains (NTB) tissues were analyzed and compared each other. The relationship of degrees of the methylation with the gene expression and prognosis in the patients with GBMs were analyzed. Results Three datasets of GBM (n=509) and NTB (n=37) were acquired respectively from the databases. The CpGs at non-CGI regions of TRIM38 was significantly hypomethylated in GBMs tissues compared that in NTB tissues (P<0.05). The DNA methylation of the CpGs was negatively related with TRIM38 expression (P<0.05). The included patients were divided into both the subgroups with TRIM38 hypermethylated and hypomethylated tumors. The overall survival time was significantly longer in the subgroup with hypermethylated tumors than that in the subgroup with hypomethylated tumors (P<0.05).The multivariate Cox models suggested that TRIM38 non-CGI DNA methylation was a independent factor related to the prognosis in the patients with GBMs (P<0.05). The bioinfomatic analysis showed that the subgroup with TRIM38 hypomethylated tumors was enriched with gene sets related to immune process regulation and toll-like receptors signaling. Conclusion Taking TRIM38 as an example, this study highlighted the potential significance of non-CGI DNA methylation alterations in gene expression and prognosis in the patients with GBMs.

参考文献/References:

[1] Yin AA, Cheng JX, Zhang X, et al. The treatment of gliobla- stomas: a systematic update on clinical Phase Ⅲ trialsm [J]. Crit Rev Oncol Hematol, 2013, 87(3): 265-282.
[2] Yin AA, Lu N, Etcheverry A, et al. A novel prognostic six- CpG signature in glioblastomas [J]. CNS Neurosci Ther, 2018, 24: 167-177.
[3] 康恩铭，章　薇，章　翔. 甲基化状态风险分析对胶质母细胞瘤患者预后评价意义[J]. 中华神经外科疾病研究杂志，2018，17（1）：27-31.
[4] Ehrlich M. DNA hypomethylation in cancer cells [J]. Epige- nomics, 2009, 1(2): 239-259.
[5] Brennan CW, Verhaak RG, Mckenna A, et al. The somatic genomic landscape of glioblastoma [J]. Cell, 2013, 155(2): 462-477.
[6] Etcheverry A, Aubry M, de Tayrac M, et al. DNA methyla- tion in glioblastoma: impact on gene expression and clinical outcome [J]. BMC Genomics, 2010, 11: 701-712.
[7] Zhang W, Yan W, You G, et al. Genome-wide DNA methy- lation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma [J]. Cancer Lett, 2013, 328(1): 120-125.
[8] Horvath S, Garagnani P, Bacalini M G, et al. Accelerated epigenetic aging in Down syndrome [J]. Aging Cell, 2015, 14(3): 491-495.
[9] Hu MM, Shu HB. Multifaceted roles of TRIM38 in innate immune and inflammatory responses [J]. Cell Mol Immunol, 2017, 14(4): 331-338.
[10] Deng S, Zhu S, Qiao Y, et al. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma [J]. Protein Cell, 2014, 5(12): 899-911.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(02):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(02):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(02):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(02):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(02):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(02):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
[10]杨雅婷　李　晖.AEBP1在胶质母细胞瘤中的表达及临床意义[J].中国临床神经外科杂志,2020,(08):521.[doi:10.13798/j.issn.1009-153X.2020.08.008]
　YANG Ya-ting,LI Hui..Expression of AEBP1 in human glioblastoma tissues and its clinical significance[J].,2020,(02):521.[doi:10.13798/j.issn.1009-153X.2020.08.008]

备注/Memo

备注/Memo:
（2019-02-12收稿，2019-10-20修回）
更新日期/Last Update: 2020-02-25